Universal DX (UDX) has completed its Series B funding round, which will support the clinical trial for its colorectal cancer screening blood test, Signal-C®. This trial is a key step toward securing FDA premarket approval and advancing the company’s mission…
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on utilizing patients’ own biology to treat rare diseases, has announced the online publication of data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial in…
Concentra®, a leading provider of occupational medicine, has announced the introduction of its new behavioral health service on Concentra Telemed®, the company’s telemedicine platform for workers’ compensation. Concentra® has introduced a behavioral health service to its Concentra Telemed® platform, enhancing…
Ontrak, Inc. (NASDAQ: OTRK), a top AI-driven and telehealth-enabled behavioral healthcare company, has earned HITRUST Risk-based, 2-year (r2) certification for the customer data exchange components of its Ontrak Advanced Engagement System. This certification highlights Ontrak’s steadfast dedication to upholding the…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that the European Medicines Agency (EMA) has validated their Marketing Authorization Application (MAA) for sebetralstat, an investigational oral plasma kallikrein inhibitor intended for the on-demand treatment of hereditary angioedema (HAE). The application will…
Francisco Partners, a global investment firm specializing in technology and healthcare, has announced the sale of QGenda to Hearst. Financial terms of the deal were not disclosed. QGenda, a leader in healthcare workforce management, serves over 700,000 providers across 45…
Syros Pharmaceuticals (NASDAQ: SYRS) has announced it will halt enrollment in the SELECT-AML-1 Phase 2 trial, which is assessing the triplet combination of tamibarotene, venetoclax, and azacitidine versus the doublet regimen of venetoclax and azacitidine for newly diagnosed, unfit AML…
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced the appointment of Paul A. LaViolette to its Board of Directors. Mr. LaViolette will serve as Co-Chairman alongside Robert W. Duggan, bringing his expertise as an independent director to the role. Pulse Biosciences…
Lobe Sciences Ltd (CSE: LOBE, OTCQB: LOBEF) has announced the election of a new board of directors following its annual general meeting. Shareholders elected Dr. Frederick D. Sancilio, Dr. Harry Jacobson, and Mr. Wesley Ramjeet to the board. Additionally, Mr.…
Astria Therapeutics, Inc. (NASDAQ: ATXS), a biopharmaceutical company dedicated to advancing treatments for allergic and immunological diseases, has announced its partnership with Ypsomed for developing an autoinjector for STAR-0215. This collaboration aims to enhance the delivery system for STAR-0215, a…
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) has provided an update regarding the March 2024 recall of its t:connect mobile app for Apple iOS devices. The recall addresses an issue causing rapid depletion of the t:slim X2 insulin pump battery, potentially…
Zura Bio Limited (Nasdaq: ZURA), a clinical-stage immunology company specializing in dual-pathway antibodies for autoimmune and inflammatory diseases, has completed its exchange offer and consent solicitation for its outstanding IPO warrants. This includes both public warrants, which trade under the…